# Test Criteria: 170.315.f.6 – Transmission to Public Health Agencies – Antimicrobial Use and Resistance Reporting

|  |  |
| --- | --- |
| **Testing Result** |  |
| Participant and Product-with-version |  |
| Setting | Inpatient only |
| Test Proctor |  |
| Test Date |  |
| Test Result | Pass:  Fail:  No Attempt: |
| Error Description (if applicable) |  |
| Modifications to Product Under Test |  |
| Additional Software Used |  |
| Additional Proctor Notes |  |

### Overview

In this document you will find:

* [Test Data and Test Tools](#_Test_Data_and)
* [Standards Support](#_Demonstrate_Standards_Support)
* [Drummond Test Report (Instructions, Expected Results, Points to Remember)](#_170.315(f)(6)__Transmission)
* [Test Procedures](#_1.1_Create_Antimicrobial)
* [Appendix A: Testing Guide](#_Appendix_A:_Testing)
* [Appendix B: ONC Criteria](#_Appendix_B:_ONC)

### Version of ONC Test Method

1.0

### Scope of Proctoring Sheet

The ONC test method associated with this criterion is the only approved test method for EHR Meaningful Use certification. This Proctoring Sheet is not a replacement test method but a test procedure document for performing the ONC test method and recording the results. Proctoring Sheet describe test data, test criteria and expected results. It is assumed the Health IT developer or Participant under Test is familiar with the associated ONC test method.

# Robustness and Reliability Requirement

To satisfy the module criteria, it is expected that the Product-Under-Test is able to complete the testing requirements reliably, including repeat testing with the same result without error, and with a satisfactory level of robustness. This includes unexpected error messages produced through normal operation, multiple unintended restarts of the application or any other “buggy” facets of the product displayed while testing. These errors are record in the Additional Proctor Notes of the proctor sheet. Lack of reliability and robustness of design will result in failure of the module.

# Test Data and Tools

|  |  |
| --- | --- |
| **Test Data Source:** | ONC-Supplied  DG-Supplied:  Developer-Supplied: |
| **Pre-Test Data Setup:**  Health IT developer creates (1) patient record with required standards identified below. | |
| **Test Data:**  Developer-supplied. | |
| **Test Tools:**  [CDC's NHSN CDA Validator](https://github.com/brhoAtCDC/HAI_Validator_4_MU3). This test tool requires local installation for pre-testing. User guide provided within test tool package (.zip). | |

# Demonstrate Standards Support

|  |  |
| --- | --- |
| **Test Result:** | PASS:  FAIL:  No Attempt: |
| **Instructions:** Implement standards below for Antimicrobial Use and Resistance Reporting content. | |

|  |  |  |
| --- | --- | --- |
|  | **Standard** |  |
|  | §170.205(r)(1) | HL7 Implementation Guide for CDA® Release 2 – Level 3: Healthcare Associated Infection Reports, Release 1, U.S. Realm. Technology is only required to conform to the following sections of the implementation guide:   1. HAI Antimicrobial Use and Resistance (AUR) Antimicrobial Resistance Option (ARO) Report (Numerator) specific document template in Section 2.1.2.1 (pages 69-72) 2. Antimicrobial Resistance Option (ARO) Summary Report (Denominator) specific document template in Section 2.1.1.1 (pages 54-56); and 3. Antimicrobial Use (AUP) Summary Report (Numerator and Denominator) specific document template in Section 2.1.1.2 (pages 56-58). |

# 170.315(f)(6) Transmission to Public Health – Antimicrobial Use and Resistance Reporting

|  |  |
| --- | --- |
| **Test Result:** | PASS:  FAIL:  No Attempt: |
| **Instructions:** Create antimicrobial use and resistance reporting information for electronic transmission. | |
| **Expected Test Result:**   * Create antimicrobial use and resistance reporting information in accordance with the following sections of the standard specified at §170.205(r)(1) HL7 Implementation Guide for CDA® Release 2 – Level 3: Healthcare Associated Infection Reports, Release 1, U.S. Realm. Technology is only required to conform to the following sections of the implementation guide: * HAI Antimicrobial Use and Resistance (AUR) Antimicrobial Resistance Option (ARO) Report (Numerator) specific document template in Section 2.1.2.1 (pages 69-72) * Antimicrobial Resistance Option (ARO) Summary Report (Denominator) specific document template in Section 2.1.1.1 (pages 54-56); and * Antimicrobial Use (AUP) Summary Report (Numerator and Denominator) specific document template in Section 2.1.1.2 (pages 56-58). | |
| **Points to Remember:**   * This criterion applies to technology in the inpatient setting. * For support with the testing and/or the test tool for this criterion, please contact CDC at NHSNCD@cdc.gov. | |

**Test Procedures**

### 1.1 Create Antimicrobial use and Resistance Reporting Information

|  |  |
| --- | --- |
|  | User accesses patient record containing pre-loaded antimicrobial use and resistance reporting data or inputs data in patient record. |
|  | User generates Antimicrobial Use and Resistance reporting information for the specified three sections of the HL7 Implementation Guide for CDA® Release 2 – Level 3: Healthcare Associated Infection (HAI) Reports, Release 1, U.S. Realm, August 2013:   * HAI Antimicrobial Use and Resistance (AUR) Antimicrobial Resistance Option (ARO) Report (Numerator) specific document template in Section 2.1.2.1 (pages 69-72); * Antimicrobial Resistance Option (ARO) Summary Report (Denominator) specific document template in Section 2.1.1.1 (pages 54-56); and * Antimicrobial Use (AUP) Summary Report (Numerator and Denominator) specific document template in Section 2.1.1.2 (pages 56-58). |
|  | Proctor uploads each reporting document into the [CDC's NHSN CDA Validator](https://github.com/brhoAtCDC/HAI_Validator_4_MU3) tool for validation. |

<INSERT SCREEN SHOTS>

# Appendix A: Testing Guide

*This appendix contains more details and background on the testing requirements, including explanation on underlying standards, notable issues and best practice suggestions.*

Rev 01-Mar-2016 Additions

* Antimicrobial Use and Reporting Resistance is designed to for electronic transmission to CDC’s National Healthcare Safety Network (NHSN). This information is to only be collected by the CDC at the national level rather than at the jurisdictional level.

# Appendix B: ONC Criteria and Standards

*This appendix contains copy of the relevant ONC criteria and standards for this proctor sheet as a reference. In the event of a discrepancy with the ONC Final Rule, the ONC Final Rule takes precedence.*

**§170.315(f)(6) Transmission to Public Health Agencies – Antimicrobial Use and Resistance Reporting**

Technology must be able to create case reporting information for electronic transmission.

**§170.205(r)(1)** Standard. The following sections of HL7 Implementation Guide for CDA® Release 2 – Level 3: Healthcare Associated Infection Reports, Release 1, U.S. Realm. Technology is only required to conform to the following sections of the implementation guide:

(i) HAI Antimicrobial Use and Resistance (AUR) Antimicrobial Resistance Option (ARO) Report (Numerator) specific document template in Section 2.1.2.1 (pages 69-72);

(ii) Antimicrobial Resistance Option (ARO) Summary Report (Denominator) specific document template in Section 2.1.1.1 (pages 54-56); and

(iii) Antimicrobial Use (AUP) Summary Report (Numerator and Denominator) specific document template in Section 2.1.1.2 (pages 56-58).

# Change Log

|  |  |
| --- | --- |
| Revision | Change Description |
| 01-Mar-2017 | Added clarification that this criterion is for the inpatient setting only. |
| 01-Mar-2016 | Initial Release |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

**About Drummond Group LLC**

Drummond Group LLC is a global software test and certification lab that serves a wide range of vertical industries.  In healthcare, Drummond Group tests and certifies Controlled Substance Ordering Systems (CSOS), Electronic Prescription of Controlled Substances (EPCS) software and processes, and Electronic Health Records (EHRs) – designating the trusted test lab as the only third-party certifier of all three initiatives designed to move the industry toward a digital future. Founded in 1999, and accredited for the Office of the National Coordinator Health IT Certification Program as an Authorized Certification Body (ACB) and an Authorized Test Lab (ATL), Drummond Group continues to build upon its deep experience and expertise necessary to deliver reliable and cost-effective services. For more information, please visit <http://www.drummondgroup.com> or email [ehr@drummondgroup.com](mailto:ehr@drummondgroup.com)

END OF DOCUMENT